Detalles de la búsqueda
1.
Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: a multicenter retrospective study.
Cancer Immunol Immunother
; 72(7): 2169-2178, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-36849845
2.
[Efficacy of Primary Prophylaxis with Pegfilgrastim after Docetaxel for Castration-Resistant Prostate Cancer].
Gan To Kagaku Ryoho
; 46(11): 1721-1725, 2019 Nov.
Artículo
en Japonés
| MEDLINE | ID: mdl-31748481
3.
A prospective, observational, multicenter study on risk factors and prophylaxis for low emetic risk chemotherapy-induced nausea and vomiting.
Support Care Cancer
; 25(9): 2707-2714, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28341971
4.
Predictors for the Clinical Efficacy of Tramadol for Cancer Pain.
Am J Hosp Palliat Care
; 40(12): 1303-1309, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36647180
5.
Association between pretreatment neutrophil-to-lymphocyte ratio and immune-related adverse events due to immune checkpoint inhibitors in patients with non-small cell lung cancer.
Thorac Cancer
; 12(15): 2198-2204, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34173724
6.
Influence of proton pump inhibitors and H2-receptor antagonists on the efficacy and safety of dasatinib in chronic myeloid leukemia patients.
Int J Hematol
; 111(6): 826-832, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32152877
7.
Risk factors for delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy: a prospective, observational, multicenter study.
Cancer Manag Res
; 10: 4249-4255, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30323680
Resultados
1 -
7
de 7
1
Próxima >
>>